11.12
+0.71(+6.82%)
Currency In USD
| Previous Close | 10.41 |
| Open | 10.43 |
| Day High | 11.21 |
| Day Low | 10.37 |
| 52-Week High | 14.67 |
| 52-Week Low | 3.9 |
| Volume | 1.16M |
| Average Volume | 1.08M |
| Market Cap | 1.08B |
| PE | -5.88 |
| EPS | -1.89 |
| Moving Average 50 Days | 10.39 |
| Moving Average 200 Days | 8.62 |
| Change | 0.71 |
If you invested $1000 in ORIC Pharmaceuticals, Inc. (ORIC) since IPO date, it would be worth $431.51 as of September 28, 2025 at a share price of $11.12. Whereas If you bought $1000 worth of ORIC Pharmaceuticals, Inc. (ORIC) shares 3 years ago, it would be worth $3,421.54 as of September 28, 2025 at a share price of $11.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer
GlobeNewswire Inc.
Aug 18, 2025 8:05 PM GMT
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today anno
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC
GlobeNewswire Inc.
May 28, 2025 8:05 PM GMT
Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC PSA responses were observed across
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
GlobeNewswire Inc.
May 28, 2025 8:05 PM GMT
Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capital Pro forma